AOCNP Advanced Oncology Certified Nurse
Practitioner Exam 2026 | Practice Questions,
Verified Answers & Detailed Rationales |
Oncology Certification Study Guide | Just
Released This Year PDF | Updated This Year
AOCNP ADVANCED ONCOLOGY CERTIFIED NURSE PRACTITIONER EXAM 2026 |
PRACTICE QUESTIONS, VERIFIED ANSWERS & DETAILED RATIONALES
• This comprehensive study guide contains 200 verified practice questions with
detailed rationales designed to mirror the AOCNP certification exam structure,
covering all major oncology topics and clinical scenarios.
• Study this material by reviewing each question carefully, attempting answers
before checking the correct answer, and thoroughly reading the rationale to
reinforce concepts and clinical decision-making required for AOCNP certification.
QUESTION 1
A 62-year-old male with newly diagnosed stage IIIB non-small cell lung cancer
presents to your clinic. He has a 45 pack-year smoking history and baseline
ECOG performance status of 1. When counseling this patient regarding
treatment options, which statement BEST reflects current standard of care
for this disease stage?
A) Chemotherapy alone is the recommended first-line treatment for all stage IIIB
NSCLC patients
B) Concurrent chemoradiation followed by durvalumab consolidation is an
evidence-based approach for unresectable stage III NSCLC
C) Surgery should be considered as the primary treatment modality for all patients
with stage IIIB disease
D) Immunotherapy monotherapy is superior to chemoradiation for improving
overall survival
E) Palliative care should be initiated immediately without pursuing curative
treatment
,✓ B) Concurrent chemoradiation followed by durvalumab consolidation is an
evidence-based approach for unresectable stage III NSCLC
Rationale: The PACIFIC trial demonstrated that adding durvalumab (an anti-PD-L1
checkpoint inhibitor) consolidation therapy after concurrent chemoradiation
significantly improved overall and progression-free survival in patients with
unresectable stage III NSCLC. This combination approach has become the standard
of care for inoperable stage IIIB disease. Option A is incomplete as chemotherapy
alone without radiation is suboptimal for stage III disease. Option C is incorrect
because many stage IIIB tumors are unresectable due to extent and location.
Option D is not supported by current evidence showing chemoradiation followed
by durvalumab is superior. Option E is premature as this patient has good
performance status and should pursue curative intent treatment.
QUESTION 2
A 58-year-old woman with metastatic breast cancer is being considered for
treatment with trastuzumab (Herceptin). Which of the following is the MOST
appropriate first step before initiating this therapy?
A) Obtain baseline ECG and echocardiogram to assess left ventricular ejection
fraction
B) Initiate treatment immediately as HER2 testing is rarely inaccurate
C) Obtain HER2 status through FISH or immunohistochemistry testing
D) Start prophylactic dexrazoxane to prevent cardiotoxicity
E) Obtain chest X-ray to assess for pulmonary metastases
✓ C) Obtain HER2 status through FISH or immunohistochemistry testing
Rationale: Before initiating trastuzumab therapy, HER2 status must be confirmed
through fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC)
testing. Trastuzumab is only indicated for HER2-positive tumors, making this testing
essential for appropriate patient selection and safety. While baseline cardiac
assessment (Option A) is important and should be performed, HER2 status
,confirmation must come first. Option B is dangerous as HER2 testing can be
inaccurate if not properly performed. Option D is not standard practice as
dexrazoxane has limited evidence and is not routinely given prophylactically.
Option E is not necessary before initiating therapy.
QUESTION 3
A 71-year-old male with colorectal cancer metastatic to the liver is starting 5-
fluorouracil (5-FU)-based chemotherapy. Which of the following patients
would be at HIGHEST risk for severe 5-FU toxicity?
A) Patient with wild-type DPYD gene status
B) Patient with heterozygous DPYD mutation
C) Patient with normal renal function and liver function
D) Patient who has previously tolerated 5-FU without complications
E) Patient with normal albumin levels
✓ B) Patient with heterozygous DPYD mutation
Rationale: Dihydropyrimidine dehydrogenase (DPYD) is the enzyme responsible for
metabolizing 5-FU. Patients with DPYD deficiency or mutations are at significantly
elevated risk for severe 5-FU toxicity, including neutropenia, diarrhea, and hand-
foot syndrome. Heterozygous DPYD mutations confer moderate to high risk. DPYD
testing is now recommended before initiating 5-FU therapy. Patients with wild-type
DPYD (Option A) have normal metabolism and lower risk. Options C and E
represent normal organ function, which reduces toxicity risk. Option D suggests
previous tolerance, which would not predispose to current toxicity.
QUESTION 4
A 45-year-old woman is diagnosed with triple-negative breast cancer (TNBC)
and has a BRCA1 mutation. Which therapy has shown the GREATEST survival
benefit in this population?
, A) Platinum-based chemotherapy combined with olaparib maintenance
B) Endocrine therapy with tamoxifen
C) Trastuzumab-based therapy alone
D) Radiation therapy without systemic therapy
E) Surveillance without systemic treatment
✓ A) Platinum-based chemotherapy combined with olaparib maintenance
Rationale: BRCA-mutated triple-negative breast cancer tumors are sensitive to
platinum agents and PARP inhibitors. Platinum-based chemotherapy followed by
PARP inhibitor maintenance (such as olaparib) has demonstrated significant
survival benefits in BRCA1/2-mutated breast cancer. This combination therapy
takes advantage of the tumor's homologous recombination deficiency. Option B
(tamoxifen) is ineffective in TNBC as these tumors lack ER/PR expression. Option C
(trastuzumab) is used in HER2-positive cancers, not TNBC. Options D and E are
insufficient treatment for this aggressive malignancy.
QUESTION 5
A 68-year-old man with metastatic prostate cancer is starting sipuleucel-T
(Provenge) immunotherapy. Which statement BEST describes the mechanism
of action of this therapy?
A) It blocks checkpoint inhibitors to release T-cell exhaustion
B) It is a personalized autologous dendritic cell vaccine that primes immune
responses against prostate cancer antigens
C) It is a monoclonal antibody targeting androgen receptors
D) It enhances chemotherapy cytotoxicity through immune enhancement
E) It directly kills cancer cells through apoptosis induction
✓ B) It is a personalized autologous dendritic cell vaccine that primes immune
responses against prostate cancer antigens
Practitioner Exam 2026 | Practice Questions,
Verified Answers & Detailed Rationales |
Oncology Certification Study Guide | Just
Released This Year PDF | Updated This Year
AOCNP ADVANCED ONCOLOGY CERTIFIED NURSE PRACTITIONER EXAM 2026 |
PRACTICE QUESTIONS, VERIFIED ANSWERS & DETAILED RATIONALES
• This comprehensive study guide contains 200 verified practice questions with
detailed rationales designed to mirror the AOCNP certification exam structure,
covering all major oncology topics and clinical scenarios.
• Study this material by reviewing each question carefully, attempting answers
before checking the correct answer, and thoroughly reading the rationale to
reinforce concepts and clinical decision-making required for AOCNP certification.
QUESTION 1
A 62-year-old male with newly diagnosed stage IIIB non-small cell lung cancer
presents to your clinic. He has a 45 pack-year smoking history and baseline
ECOG performance status of 1. When counseling this patient regarding
treatment options, which statement BEST reflects current standard of care
for this disease stage?
A) Chemotherapy alone is the recommended first-line treatment for all stage IIIB
NSCLC patients
B) Concurrent chemoradiation followed by durvalumab consolidation is an
evidence-based approach for unresectable stage III NSCLC
C) Surgery should be considered as the primary treatment modality for all patients
with stage IIIB disease
D) Immunotherapy monotherapy is superior to chemoradiation for improving
overall survival
E) Palliative care should be initiated immediately without pursuing curative
treatment
,✓ B) Concurrent chemoradiation followed by durvalumab consolidation is an
evidence-based approach for unresectable stage III NSCLC
Rationale: The PACIFIC trial demonstrated that adding durvalumab (an anti-PD-L1
checkpoint inhibitor) consolidation therapy after concurrent chemoradiation
significantly improved overall and progression-free survival in patients with
unresectable stage III NSCLC. This combination approach has become the standard
of care for inoperable stage IIIB disease. Option A is incomplete as chemotherapy
alone without radiation is suboptimal for stage III disease. Option C is incorrect
because many stage IIIB tumors are unresectable due to extent and location.
Option D is not supported by current evidence showing chemoradiation followed
by durvalumab is superior. Option E is premature as this patient has good
performance status and should pursue curative intent treatment.
QUESTION 2
A 58-year-old woman with metastatic breast cancer is being considered for
treatment with trastuzumab (Herceptin). Which of the following is the MOST
appropriate first step before initiating this therapy?
A) Obtain baseline ECG and echocardiogram to assess left ventricular ejection
fraction
B) Initiate treatment immediately as HER2 testing is rarely inaccurate
C) Obtain HER2 status through FISH or immunohistochemistry testing
D) Start prophylactic dexrazoxane to prevent cardiotoxicity
E) Obtain chest X-ray to assess for pulmonary metastases
✓ C) Obtain HER2 status through FISH or immunohistochemistry testing
Rationale: Before initiating trastuzumab therapy, HER2 status must be confirmed
through fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC)
testing. Trastuzumab is only indicated for HER2-positive tumors, making this testing
essential for appropriate patient selection and safety. While baseline cardiac
assessment (Option A) is important and should be performed, HER2 status
,confirmation must come first. Option B is dangerous as HER2 testing can be
inaccurate if not properly performed. Option D is not standard practice as
dexrazoxane has limited evidence and is not routinely given prophylactically.
Option E is not necessary before initiating therapy.
QUESTION 3
A 71-year-old male with colorectal cancer metastatic to the liver is starting 5-
fluorouracil (5-FU)-based chemotherapy. Which of the following patients
would be at HIGHEST risk for severe 5-FU toxicity?
A) Patient with wild-type DPYD gene status
B) Patient with heterozygous DPYD mutation
C) Patient with normal renal function and liver function
D) Patient who has previously tolerated 5-FU without complications
E) Patient with normal albumin levels
✓ B) Patient with heterozygous DPYD mutation
Rationale: Dihydropyrimidine dehydrogenase (DPYD) is the enzyme responsible for
metabolizing 5-FU. Patients with DPYD deficiency or mutations are at significantly
elevated risk for severe 5-FU toxicity, including neutropenia, diarrhea, and hand-
foot syndrome. Heterozygous DPYD mutations confer moderate to high risk. DPYD
testing is now recommended before initiating 5-FU therapy. Patients with wild-type
DPYD (Option A) have normal metabolism and lower risk. Options C and E
represent normal organ function, which reduces toxicity risk. Option D suggests
previous tolerance, which would not predispose to current toxicity.
QUESTION 4
A 45-year-old woman is diagnosed with triple-negative breast cancer (TNBC)
and has a BRCA1 mutation. Which therapy has shown the GREATEST survival
benefit in this population?
, A) Platinum-based chemotherapy combined with olaparib maintenance
B) Endocrine therapy with tamoxifen
C) Trastuzumab-based therapy alone
D) Radiation therapy without systemic therapy
E) Surveillance without systemic treatment
✓ A) Platinum-based chemotherapy combined with olaparib maintenance
Rationale: BRCA-mutated triple-negative breast cancer tumors are sensitive to
platinum agents and PARP inhibitors. Platinum-based chemotherapy followed by
PARP inhibitor maintenance (such as olaparib) has demonstrated significant
survival benefits in BRCA1/2-mutated breast cancer. This combination therapy
takes advantage of the tumor's homologous recombination deficiency. Option B
(tamoxifen) is ineffective in TNBC as these tumors lack ER/PR expression. Option C
(trastuzumab) is used in HER2-positive cancers, not TNBC. Options D and E are
insufficient treatment for this aggressive malignancy.
QUESTION 5
A 68-year-old man with metastatic prostate cancer is starting sipuleucel-T
(Provenge) immunotherapy. Which statement BEST describes the mechanism
of action of this therapy?
A) It blocks checkpoint inhibitors to release T-cell exhaustion
B) It is a personalized autologous dendritic cell vaccine that primes immune
responses against prostate cancer antigens
C) It is a monoclonal antibody targeting androgen receptors
D) It enhances chemotherapy cytotoxicity through immune enhancement
E) It directly kills cancer cells through apoptosis induction
✓ B) It is a personalized autologous dendritic cell vaccine that primes immune
responses against prostate cancer antigens
